Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Healthy Volunteer
Interventions: RO4917523, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiometabolic Disease
Interventions: AMG 513, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Anaheim, California • Lake Forest, California • Oxnard, California + 9 more

Conditions: Chronic Low-back Pain
Interventions: Spinal Manipulation Therapy (SMT), Naloxone, Placebo, Mindfulness Based Stress Reduction Therapy (MT); Other · Drug · Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Nashville, Tennessee

Conditions: Brain Cancer
Interventions: erlotinib, Cytoreductive Surgery; Drug · Procedure
Lead sponsor: Andrew B Lassman, MD; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: High Risk Pregnancy, Congenital Heart Disease, Fetal Hydrops, Twin Monochorionic Monoamniotic Placenta, Gastroschisis, Fetal Demise, Stillbirth, Fetal Arrhythmia, Long QT Syndrome, Intrauterine Fetal Death, Sudden Infant Death, Pregnancy Loss, Twin Twin Transfusion Syndrome, Birth Defect, Fetal Cardiac Anomaly, Fetal Cardiac Disorder, Fetal Death, Brugada Syndrome, Fetal Tachycardia
Interventions: Fetal Magnetocardiogram and Neonatal Electrocardiogram, Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally; Diagnostic Test · Genetic
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
Interventions: Azacitidine, Pevonedistat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Infections, Bacterial
Interventions: GSK2140944 (Single dose), GSK2140944 (Multiple dose); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dyslipidemia
Interventions: CAT 2003, Placebo; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Epstein-Barr Virus Infection
Interventions: mRNA-1189, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 10 Years to 30 Years
Enrollment: 867 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 65
States / cities: Huntsville, Alabama • Anaheim, California • Colton, California + 56 more

Conditions: Opioid Misuse, Opioid-Related Disorders, Pharmacist-Patient Relations
Interventions: Patient Navigation, Standard Medication Counseling (SMC); Behavioral · Other
Lead sponsor: Jerry Cochran; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hypertension
Interventions: Tonlamarsen, Placebo; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 39
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 36 more

Conditions: Alopecia Areata
Interventions: CTP-543, Placebo; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 35 more

Conditions: HIV Infection
Interventions: Atazanavir + Ritonavir + Combivir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: West Palm Beach, Florida • Houston, Texas

Conditions: Shift-work Disorder
Interventions: Active phototherapy, Control phototherapy, Cognitive Behavioral Therapy (CBT), Sleep education control; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: Vitamin B1 Deficiency, Thiamine Deficiency
Interventions: Trimethoprim, Metformin, Vitamin B1; Drug · Dietary Supplement
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype, Adult T-Cell Leukemia/Lymphoma (ATLL)
Interventions: Cobomarsen; Drug
Lead sponsor: miRagen Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 19
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 15 more

Conditions: Non Small Cell Lung Cancer
Interventions: Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin, Pharmacokinetic sampling - rosuvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550; Procedure · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Small Cell Lung Cancer
Interventions: LY2523355, Granulocyte colony-stimulating factor (G-CSF); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Torrington, Connecticut • Athens, Georgia • Marietta, Georgia + 5 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 Inhibitor (DPP-4), Glucagon-Like Peptide-1 Agonist (GLP-1), Thiazolidinedione (TZD), Sulfonylureas, Insulin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 25,358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Trevose, Pennsylvania

Conditions: Dental Caries
Interventions: NaF, SnF, NaMFP; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
Interventions: Vimseltinib, Placebo; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 11
States / cities: Duarte, California • Sacramento, California • Aurora, Colorado + 8 more

Conditions: Axial Spondyloarthrithis, Ankylosing Spondylitis
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 16
States / cities: Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more

Conditions: Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms, ER Positive Breast Cancer, Cervical Cancers, Cervical Neoplasms, Cervical Carcinoma, Triple Negative Breast Cancer, Gynecologic Cancers, Gynecologic Neoplasm, Endometrial Cancer, Endometrial Neoplasm, Endometrial Carcinoma (EC), Fallopian Cancer, Ovarian Carcinoma, Ovarian Cancer, Ovarian Neoplasms, Prostate Cancers, Prostate Carcinoma, Solid Tumors, Neoplasms, Neoplasms by Site, Breast Diseases, Uterine Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms
Interventions: ATV-1601, ATV-1601 + Fulvestrant; Drug · Combination Product
Lead sponsor: Atavistik Bio, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Lake Mary, Florida • Boston, Massachusetts + 2 more

Conditions: Vestibular Disorder, Hearing Loss, Sensorineural
Interventions: Dynamic Visual Acuity, Reading Outcomes, Static Visual Acuity; Behavioral
Lead sponsor: Father Flanagan's Boys' Home; Other
Eligibility: 7 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Omaha, Nebraska

Search by objective public record fields.

A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944

A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

Healthy Opioid Prescription Engagement

A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

Role of Sleep Reactivity in Shift Work Disorder

The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer

A Study for Participants With Small-Cell Lung Cancer

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Enamel Remineralization Potential of Dentifrices in Situ

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Reading Outcomes in Children With Vestibular Loss